Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

Journal of Clinical Investigation

Volumn 101, Issue 6, 1998, Pages 1354-1361

  Okuno, Akira ^a,b   Tamemoto, Hiroyuki ^a   Tobe, Kazuyuki ^a   Ueki, Kohjiro ^a   Mori, Yasumichi ^a   Iwamoto, Keiji ^a,e   Umesono, Kazuhiko ^c   Akanuma, Yasuo ^d   Fujiwara, Toshihiko ^c   Horikoshi, Hiroyoshi ^b   Yazaki, Yoshio ^a   Kadowaki, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^d INSTITUTE FOR ADULT DISEASES   (Japan)

^e TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Adipocyte; Insulin resistance; Obesity; Peroxisome proliferator activated receptor ; Thiazolidinedione

Indexed keywords

GLUCOSE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRIACYLGLYCEROL; TROGLITAZONE;

ADIPOCYTE; ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; DRUG MECHANISM; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; WHITE ADIPOSE TISSUE;

EID: 0032520921     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1235     Document Type: Article

References (50)

1. Iwamoto, Y., T. Kuzuya, A. Matsuda, T. Awata, S. Kumakura, G. Inooka, and I. Shiraishi. 1991. Effect of new antidjahetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
2. Saltiel, A.R., and J.M. Olefsky. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661-1669.
3. Suter, S.L., J.J. Nolan, P. Wallance, B. Gumbiner, and J.Y. Olefsky. 1992. Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
4. Kumar, S., A.J.M. Boulton, H. Beck-Nielsen, F. Berthezene, M. Muggeo, B. Persson, G.A. Spinas, S. Donoghue, S. Lettis, and P. Stewart-Long. 1996. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetoloigia. 39:701-709.
5. Fujiwara, T., S. Yoshioka, T. Yoshioka, I. Ushiyama, and H. Horikoshi. 1988. Characterization of new oral antidiabetic agent CS-045; studies in KK and ob/ob mice and Zucker fatty rats. Diahetes. 37:1549-1558.
6. Fujiwara, T., A. Okuno, S. Yoshioka, and H. Horikoshi. 1995. Suppression of hepatic gluconeogenesis in long-term Troglitazone-treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism. 44:486-490.
7. Kellerer, M., G. Kroder, S. Tippmer, L. Berti, R. Kiehn, L. Mosthaf, and H. Haring. 1994. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes. 43:447-453.
8. Taylor, S.I., V. Barr, and M. Reitman. 1996. Docs leptin contribute to diabetes caused by obesity? Science. 274:1151-1152.
9. Randle, P.J., P.B. Garland, C.N. Hales, and E.A. Newsholme. 1963. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. I:785-789.
10. Boden, G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46:3-10.
11. Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:87-91.
12. Hotamisligil, G.S., D.L., Murray, L.N. Choy, and B.M. Spiegelman. 1994. Tumor necrosis factor-α inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91:4854-1858.
13. Hotamisligil, G.S., A. Budavari, D. Murray, and B.M. Spiegelman. 1994. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J. Clin. Invest. 94:1543-1549.
14. Hotamisligil, G.S., P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science. 271:665-668.
15. Stephens, J.M., and P.H. Pekala. 1991. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-α. J. Biol. Chem. 266:21839-21845.
16. Cohen, B., D. Novick, and M. Rubinstein. 1996. Modulation of insulin activities by leptin. Science. 274:1185-1188.
17. Segal, K.R., M. Landt, and S. Klein. 1996. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes. 45: 988-991.
18. Muller, G., J. Ertl, M. Gerl, and G. Preibisch. 1997. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J. Biol. Chem. 272:10585-10593.
19. Tontonoz, P., E. Hu, and B.M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid-activated transcription factor. Cell. 79:1147-1156.
20. Braissant, O., F. Foufelle, C. Scotto, M. Dauca, and W. Whali. 1996. Differential expression of peroxisomal proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 137: 354-366.
21. Kliewer, S.A., K. Umesono, D.J. Noonan, R.A. Heyman, and R.M. Evans. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 358: 771-774.
22. Schoonians, K., B. Staels, and J. Auwerx. 1996. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302:93-109.
23. Sears, I., M.A. MacGinntie, L.G. Kovacs, and R.A. Graves. 1996. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor γ. Mol. Cell. Biol. 16:3410-3419.
24. Lehmann, J.M., L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer. 1995. An antidiabelic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activaled receptor γ. J. Bitol. Chem. 270:12953-12956.
25. Willson, T.M., J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, S.R. Prakash, K.D. Beck, L.B. Moore, S.A. Kliewer, and J.M. Lehmann. 1996. The structure-activity relationship between peroxisome proliferator-activaled receptor gamma agonism and the antihyperglycemic activity of thiazolidincdiones. J. Med. Chem. 39:665-668.
26. Berger. J., P. Bailey, C. Biswas, C.A. Cullinan, T.W. Doebber, N.S. Haves, R. Saperstein, R.G. Smith, and M.D. Leibowits. 1996. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activaled receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 137:4189-4195.
27. Apweiler, A., and P. Freund. 1993. Development of glucose intolerance in obese (fa/fa) Zucker rats. Horm. Metab. Res. 25:521-524.
28. Chomczynsky, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
29. Tontonoz, P., E. Hu, R.A. Graves, A.I. Budavari, and B.M. Spiegelman. 1994. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224-1234.
30. Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J.M. Friedman. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425-432.
31. Pennica, D., J.S. Hayflick, T.S. Bringman, M.A. Palladino, and D.V. Goeddel. 1985. Cloning and expression in Escherichia coli af the cDNA for murine tumor necrosis factor. Proc. Natl. Acad. Sci. USA. 82:6060-6064.
32. Gavrieli, Y., Y. Sherman, and S.A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:493-501.
33. Cleary, M.P., J.A. Brasel, and M.R.C. Greenwood. 1979. Developmental changes in thymidine kinase. DNA, and fat cellulariiv in Zucker rats. Am. J. Physiol. 236:E508-E513.
34. Ohsumi, J., S. Sakakibara, J. Yamaguchi, K. Miyadai, S. Yoshioka, T. Fujiwara, H. Horikoshi, and N. Serizawa. 1994. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology. 135:2279-2282.
35. Szalkowski, D., S. White-Carrington, J. Berger, and B. Zhang. 1995. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1474-1481.
36. Forman, B.M., P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans. 1995. 15-dcoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83:803-812.
37. Kliewer, S.A., J.M. Lenhard, T.M. Willson, I. Pate, D.C. Morris, and J.M. Lehmann. 1995. A prostaglandin J2 metabolite hinds peroxisomc proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:813-819.
38. Prins, J.B., N.I. Walker, C.M. Winterford, and D.P. Cameron. 1994. Apoptosis of human adipocytes in vitro. Biochem. Biophys. Res. Commun. 201: 500-507.
39. Maffei, M., H. Fei, G.-H. Lee, C. Dani, P. Leroy, Y. Zhang, R. Procnca, R. Negrel, G. Ailhaud, and J.M. Friedman. 1995. Increased expression in adipocyles of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc. Natl. Acad. Sci. USA. 92:6957-6960.
40. Hotamisligil, G.S., R.S. Johnson, R.J. Distel, R. Ellis, V.E. Papaioannou, and B.M. Spiegelman. 1996. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 274:1377-1379.
41. Pedersen, O., C.R. Kahn, and B.B. Kahn. 1992. Divergent regulation of the Glut 1 and Glut 4 glucose transporters in isolated adipocytes from Zucker rats. J. Clin. Invest. 89:1964-1973.
42. Kallen, C.B., and M.A. Lazar. 1996. Antidiabetic thiazolidinediones inhibit leptin (oh) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA. 93:5793-5796.
43. Hofmann, C., K. Lorenz, S.S. Braithwaite, J.R. Colca, B.J.J.R. Palzauk, G.S. Hotamisligil, and B.M. Spiegelman. 1994. Altered gene expression for tumor necrosis factor-α and its receptors during drug dietary modulation of insulin resistance. Endocrinology. 134:264-270.
44. Zhang, E., M.P. Graziano, T.W. Doebber, M.D. Leibowitz, S. White-Carrington, D.M. Szalkowski, P.J. Hey, M. Wu, C.A. Cullinan, P.L. Bailey, et al. 1996. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. 271:9455-9459.
45. Wang, Y., K.K. Kuropatwinski, D.W. White,T.S. Hawley, R.G. Hawley, L.A. Tartaglia, and H. Baumann. 1997. Leptin receptor action in hepatic cells. J. Biol. Chem. 272:16216-16223.
46. Olefsky, J.M. 1976. The effects of spontaneous obesity on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocyles. J. Clin. Innvest. 57:842-851.
47. Abbott, W.G., and J.E. Foley. 1987. Comparison of body composition, adipocyte size and glucose and insulin concentration in Pima Indian and Caucasian children. Metabolism. 36:576-579.
48. Sreenan, S., J. Sturis, W. Pugh, C.F. Burant, and K.S. Polonsky. 1996. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglilazone. Am. J. Physiol. 271:E742-E747.
49. Stevenson, R.W., N.J. Hutson, M.N. Krupp, R.A. Volkmann, G.S. Holland, J.F. Eggler, D.A. Clark, R.K. McPherson, K.L. Hall, B.H. Danbury, et al. 1990. Actions of novel anlidiabetic agent englilazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes. 39:1218-1227.
50. Montague, C.T., J.B. Prins, L. Sanders, J.E. Digby, and S. O'Rahilly. 1997. Depot-and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes. 46:342-347.